Joe Springer's Instablog
I got a question about JNJ's type 2 diabetes drug Invokana being approved yesterday. 3 things:
1) Afrezza works by mimicking a healthy human pancreas, carrying glucose into the cells to be used for energy.
Invokana works by excreting more sugar in the urine (sweet pee, apple of my eye!). This is obviously not optimal, and should be most useful for patients with very advanced diabetes - whereas Afrezza is in trials for early-stage on through advanced diabetes.
2) The drug is not a mealtime therapy and is not a competitor to Afrezza.
3) The approval is auspicious for Afrezza's approval.
http://seekingalpha.com/author/joe-springer/instablog
